\n\n

Authored by:Tai Hong (Tina), Guo Yu

In the drug R&D chain, compound crystals are crucial for the ultimate successful launching of pharmaceutical compounds, acting as a key node bridging technology and application. However, during the validity confirmation procedures for drug crystal patents, their legal subsistence faces high risks. According to our incomplete statistics, between 2001 and 2024, the proportion of drug crystal patents ultimately maintained as valid in invalidation cases in China was only about 23%. This data indicates that more than three-quarters of drug crystal patents failed to withstand the test of invalidation procedures after being challenged.

Read More